• Management of non–insulin-dependent diabetes mellitus (type 2) in conjunction with dietary therapy; may be used concurrently with sulfonylurea oral hypoglycemic agents.

Contraindicated in:

• Hypersensitivity
• Diabetic ketoacidosis
• Inflammatory bowel disease or other chronic intestinal conditions resulting in impaired absorption or predisposition to obstruction
• Lactation: Lactation.

Use Cautiously in:

• Patients with fever, infection, trauma, or stress (may cause hyperglycemia requiring alternate therapy)
• Renal impairment (use not recommended if creatinine >2 mg/dL)
• OB: Pedi: Safety not established.

GI: abdominal pain, diarrhea, flatulence.

Hemat: low serum iron.

Drug-Drug:

• May ↓ absorption of ranitidine and propranolol.
• Effects may be ↓ by intestinal adsorbents (such as charcoal) and digestive enzyme products; concurrent use should be avoided.

Drug-Food:

• Concurrent carbohydrates may ↑ diarrhea.

• Tablets: 25 mg; 50 mg; 100 mg;

• PO (Adults): 25 mg 3 times daily; may begin with 25 mg once daily; may be ↑ up to 100 mg 3 times daily.

Glyset

• Lowers blood glucose by inhibiting the enzyme alpha-glucosidase in the GI tract, resulting in delayed glucose absorption.

• Lowering of blood glucose in diabetic patients, especially postprandial hyperglycemia.

Therapeutic Classification: antidiabetics

Pharmacologic Classification: alpha glucosidase inhibitors

Absorption: Completely absorbed at lower doses (25 mg); 50–70% absorbed at higher doses (100 mg).

Distribution: Distributes primarily into extracellular fluid; small amounts enter breast milk.

Metabolism/Excretion: Not metabolized; action is primarily local in the GI tract; amounts that are absorbed are excreted mostly unchanged in urine.

Half-life: 2 hr.

(effect on glucose absorption)

• Instruct patient to take miglitol at the same time each day, exactly as directed.
  • Explain to patient that miglitol helps control hyperglycemia but does not cure diabetes. Therapy is usually long term.
  • Encourage patient to follow prescribed diet, medication, and exercise regimen to prevent hyperglycemic or hypoglycemic episodes.
  • Review signs of hypoglycemia and hyperglycemia with patient. If hypoglycemia occurs, advise patient to take a glass of orange juice, 2–3 tsp of sugar, honey, or corn syrup dissolved in water, and notify health care professional.
  • Instruct patient in proper testing of blood glucose or urine ketones. These tests should be monitored closely during periods of stress or illness and health care professional notified of significant changes.
  • Insulin is the recommended method of controlling blood glucose during pregnancy. Counsel female patients to use a form of contraception other than oral contraceptives and to notify health care professional promptly if pregnancy is planned or suspected.
  • Advise patient to inform health care professional of medication regimen prior to treatment or surgery.
  • Advise patient to carry a form of oral glucose (dextrose, d-glucose) and identification describing disease process and medication regimen at all times.
  • Emphasize the importance of routine follow-up exams and regular testing of blood glucose and glycosylated hemoglobin.

MI-gli-tole

NDC Code^*

• 0009- Pharmacia and Upjohn Company LLC
  • 0009-5012- Glyset
    • 0009-5012-01- 100 TABLET, FILM COATED in 1 BOTTLE (0009-5012-01)

• 0009- Pharmacia and Upjohn Company LLC
  • 0009-5013- Glyset
    • 0009-5013-01- 100 TABLET, FILM COATED in 1 BOTTLE (0009-5013-01)

• 0009- Pharmacia and Upjohn Company LLC
  • 0009-5014- Glyset
    • 0009-5014-01- 100 TABLET, FILM COATED in 1 BOTTLE (0009-5014-01)

• 57664- Sun Pharmaceutical Industries Ltd.
  • 57664-684- Miglitol
    • 57664-684-88- 100 TABLET, COATED in 1 BOTTLE (57664-684-88)

• 57664- Sun Pharmaceutical Industries Ltd.
  • 57664-685- Miglitol
    • 57664-685-88- 100 TABLET, COATED in 1 BOTTLE (57664-685-88)

• 57664- Sun Pharmaceutical Industries Ltd.
  • 57664-686- Miglitol
    • 57664-686-88- 100 TABLET, COATED in 1 BOTTLE (57664-686-88)

• 76333- Orient Pharma Co., Ltd.
  • 76333-125- Miglitol
    • 76333-125-11- 100 TABLET, COATED in 1 BOTTLE (76333-125-11)

• 76333- Orient Pharma Co., Ltd.
  • 76333-125- Miglitol
    • 76333-125-12- 1000 TABLET, COATED in 1 BOTTLE (76333-125-12)

• 76333- Orient Pharma Co., Ltd.
  • 76333-126- Miglitol
    • 76333-126-11- 100 TABLET, COATED in 1 BOTTLE (76333-126-11)

• 76333- Orient Pharma Co., Ltd.
  • 76333-126- Miglitol
    • 76333-126-12- 1000 TABLET, COATED in 1 BOTTLE (76333-126-12)

• 76333- Orient Pharma Co., Ltd.
  • 76333-127- Miglitol
    • 76333-127-11- 100 TABLET, COATED in 1 BOTTLE (76333-127-11)

• 76333- Orient Pharma Co., Ltd.
  • 76333-127- Miglitol
    • 76333-127-12- 1000 TABLET, COATED in 1 BOTTLE (76333-127-12)